MStranslate

27/01/2026

We recently had a really interesting discussion in the comments about “non-active secondary progressive multiple sclerosis”. That conversation inspired us to make a short video explaining how MS has traditionally been classified and how our understanding of what’s happening in the brain and nervous system, such as the balance between inflammation and degeneration, is changing the way we think about these labels.

26/01/2026

VOTE NOW: During a standard week, I will talk to (not message):

• 0 other people living with multiple sclerosis (react with LIKE)
• 1 - 5 other people living with multiple sclerosis (react with LOVE)
• 6+ people living with multiple sclerosis (react with WOW)

We are thinking about a potential new initiative for 2026 and are interested to know how connected our community is in an offline setting with other people living with MS.

23/01/2026

Researchers at Johns Hopkins Medicine have made a significant new discovery, which may help develop myelin repair treatments for multiple sclerosis. In this newly published study, it was found that the cells that develop into myelin-producing oligodendrocytes are continually attempting to mature, rather than only responding after injury. Understanding this mechanism is critical for the design of remyelination therapies, as it helps identify how and when drugs can best support this process.

With heavy snow predicted for this weekend in Maryland, Washington, D.C., and Virginia, please know we will be watching the weather to help keep you safe.

22/01/2026

A new study from Murdoch University has found that walking difficulties in people living with multiple sclerosis are influenced not only by physical challenges, but also by emotional and social factors.

Does this reflect your own experience?

A major Murdoch University review has found that for many people with multiple sclerosis (MS), walking is hindered not only by physical symptoms but also by external emotional and societal challenges.

21/01/2026

A small clinical trial of intranasal foralumab in people with non-active secondary progressive multiple sclerosis has shown promising results, with evidence of slowed disease progression and reduced fatigue. Based on these findings, the therapy is now expected to move into larger, placebo-controlled trials to more clearly assess its effectiveness.

20/01/2026

Last week, a new study from the Karolinska Institutet in Sweden found a new link that may help explain how Epstein-Barr Virus (EBV) leads to the development of multiple sclerosis in some people. In this research summary video, Brett discusses some of the key findings from the study.

19/01/2026

VOTE NOW: I was diagnosed with multiple sclerosis:

• 0 - 5 years ago (react with LIKE)
• 5 - 10 years ago (react with LOVE)
• 10+ years ago (react with WOW)

This information will help us better tailor the content we deliver in 2026, as well as guests that we feature on our platforms and projects that we look to launch. Your participation helps and is much appreciated!

16/01/2026

This article from McGill University is a good summary of what we know so far about the role of EBV in multiple sclerosis. However, the title is slightly misleading, as we know that the virus alone is not sufficient to cause MS (most people are infected and never develop the disease). While this is a minor issue and the article overall is very well-written, it is important that we be as precise and accurate as possible when communicating on these topics.

Multiple sclerosis is a big deal in Canada. Our country has one of the highest rates of the disease worldwide, with 290 out of every 100,000 living Canadians having received the diagnosis. To put this into perspective, imagine Montreal’s Olympic Stadium, which seats 56,040 people. If you fill the ...

15/01/2026

Two papers published this week have furthered our understanding of how Epstein-Barr Virus (EBV) may drive the development of multiple sclerosis. Determining what triggers MS may lead to more targeted treatments and enable prevention strategies that could reduce the risk of developing the disease before it starts. We will be providing full summaries of these studies next week.

13/01/2026

We have been following the Oregon Health & Science University (OHSU) study on lipoic acid as a potential multiple sclerosis treatment since the beginning. While the latest trial results found that it didn't improve walking speed in people living with progressive MS, there was a suggestion that it might slow brain atropy. Further investigation is needed to completely understand whether these benefits are worth pursuing.

OHSU-led randomized controlled trial examines benefits of over-the-counter antioxidant.

12/01/2026

The recent FDA decision to not approve tolebrutinib for the treatment of secondary progressive multiple sclerosis came as a suprise to many. In this article, we summarise their key reasons for denying the application and discuss what the likely next steps are for this therapy.

We review the decision by the FDA to not approve tolebrutinib for the treatment of secondary progressive multiple sclerosis.

09/01/2026

The results of this study from U of T Medicine may not only help better identify disease progression in people living with multiple sclerosis, but could also provide a better understanding of who may benefit from a new class of MS treatments.

A new U of T-led study has discovered a possible biomarker linked to multiple sclerosis disease progression that could help identify patients most likely to benefit from new drugs.